avelumab,pelareorep,paclitaxel
merck,pfizer,oncolytics biotech
['paclitaxel', 'bracelet-1']
more data from bracelet-1 showed confirmed orr of 37.5% for pela-paclitaxel vs 13% for paclitaxel alone &amp; 9.5 mos mpfs for pela-paclitaxel vs 6.3 mos for paclitaxel alone and a hazard ratio of 0.29. click below for the pr and kol webinar replay: #asco23
Oncolytics is developing pelareorep, an IV delivered I-O virus, promoting an inflamed tumor: waking the immune system.
Contact company directly: https://t.co/sNAsxxzRk5